Bio Techne Ownership
| TECH Stock | USD 57.41 0.77 1.32% |
Shares in Circulation | First Issued 1989-09-30 | Previous Quarter 154.9 M | Current Value 156.4 M | Avarage Shares Outstanding 152.6 M | Quarterly Volatility 12.7 M |
Bio Stock Ownership Analysis
About 100.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.83. Bio Techne Corp last dividend was issued on the 17th of November 2025. The entity had 4:1 split on the 30th of November 2022. Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. Bio-Techne operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people. To find out more about Bio Techne Corp contact Charles Kummeth at 612 379 8854 or learn more at https://www.bio-techne.com.Besides selling stocks to institutional investors, Bio Techne also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bio Techne's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bio Techne's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bio Techne Quarterly Liabilities And Stockholders Equity |
|
Bio Techne Insider Trades History
Less than 1% of Bio Techne Corp are currently held by insiders. Unlike Bio Techne's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bio Techne's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bio Techne's insider trades
Bio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bio Techne is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bio Techne Corp backward and forwards among themselves. Bio Techne's institutional investor refers to the entity that pools money to purchase Bio Techne's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Mairs & Power Inc | 2025-06-30 | 2.7 M | Champlain Investment Partners, Llc | 2025-06-30 | 2.7 M | Mackenzie Investments | 2025-06-30 | 2.6 M | Neuberger Berman Group Llc | 2025-06-30 | 2.5 M | Citadel Advisors Llc | 2025-06-30 | 2.5 M | Sumitomo Mitsui Trust Group Inc | 2025-06-30 | 2.3 M | Rgm Capital Llc | 2025-06-30 | 2.2 M | Bank Of New York Mellon Corp | 2025-06-30 | 1.9 M | Norges Bank | 2025-06-30 | 1.9 M | Vanguard Group Inc | 2025-06-30 | 18.4 M | Blackrock Inc | 2025-06-30 | 12.2 M |
Bio Techne Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Techne insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Techne's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio Techne insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bio Techne's latest congressional trading
Congressional trading in companies like Bio Techne Corp, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Bio Techne by those in governmental positions are based on the same information available to the general public.
| 2025-11-05 | Representative April Delaney | Acquired Under $15K | Verify | ||
| 2025-09-03 | Representative April Delaney | Acquired Under $15K | Verify |
Bio Techne Outstanding Bonds
Bio Techne issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bio Techne Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bio bonds can be classified according to their maturity, which is the date when Bio Techne Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Bio Techne Corporate Filings
8K | 5th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 19th of September 2025 Other Reports | ViewVerify | |
10K | 22nd of August 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.143 | Dividend Share 0.32 | Earnings Share 0.49 | Revenue Per Share | Quarterly Revenue Growth (0.01) |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.